Project Grant R01HL177563
Award Date
4/4/25
Completion Date
1/31/29
Dollars Obligated
$744K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Charlottesville, VA, USA
Similar Awards
The University of Virginia (UVA) was awarded a $161,500 Project Grant by the National Center for Advancing Translational Sciences (NCATS), CFDA #93.350, to study the role of the PHOX2B transcription factor in the respiratory chemoreceptor neurons of the mouse retrotrapezoid nucleus. The project aims to examine how wild-type and polyalanine mutant forms of PHOX2B regulate gene expression in these neurons and how that impacts respiratory control. This research could provide insights into the...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), aims to study a critical forebrain-brainstem neural circuit that facilitates the peripheral chemoreflex and contributes to hypertension associated with chronic intermittent hypoxia (CIH), a hallmark of obstructive sleep apnea. The $644,687 award to the University of Missouri System will use an integrative approach with chemogenetic and in vitro...
This K99/R00 Pathway to Independence Award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) is designed to help the principal investigator establish an independent research career focused on the neural control of breathing. The $131,733 project award period runs from September 1, 2024 to August 31, 2026. Through this grant, the researcher will study how genetic factors, specifically apolipoprotein E (APOE) alleles, influence mechanisms of...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), is funded under the Cardiovascular Diseases Research program (CFDA 93.837). The $807,067 grant will support a research project titled "Novel Physiomarkers of High-Risk Labored Breathing for Advance Warning of Clinical Deterioration". The primary objective is to develop and validate new quantitative respiratory kinematic markers that can predict the onset...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $421,800 to Midwestern University to explore the effects of chronic intermittent hypoxia, a consequence of obstructive sleep apnea, on cholinergic modulation of hypoglossal motoneurons. The project aims to determine changes in muscarinic acetylcholine receptor expression and cholinergic inputs to these neurons in response to chronic...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research (CFDA 93.837) program, provides $498,000.00 to National Jewish Health for a 3-year research project from September 1, 2024 to August 31, 2027. The objective is to generate scientific discoveries related to the role of RNA editing in regulating pulmonary endothelial cell function and its impact on the development of pulmonary hypertension, a lethal cardiovascular...
The project "NEUROIMMUNE AXIS CONTRIBUTION TO THE PATHOPHYSIOLOGY OF PULMONARY HYPERTENSION" was awarded a $498,000 Project Grant from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to the University of Florida. The 3-year project aims to evaluate the role of microglia activation and infiltration of myeloid precursor cells in the paraventricular nucleus of the hypothalamus, and how this contributes to the dysregulation of the autonomic...
This $360,100 Project Grant was awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The grant supports research to investigate the role of mu opioid receptors (MORs) and their splice variants in the neonate autoresuscitation reflex, which is linked to Sudden Infant Death Syndrome (SIDS). The research utilizes genetic knockout mouse models to examine how disruptions in OPRM1 gene expression, which encodes MORs,...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will support research conducted by The Trustees of the University of Pennsylvania to develop an innovative time-resolved MRI method for evaluating cerebral oxygen metabolism and upper airway structure in patients with obstructive sleep apnea (OSA). The $1,420,164 award, effective June 1, 2024 through April 30, 2028, will enable the researchers to:...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $484,266 to the University of Nevada, Reno (UNR) over the period of July 1, 2024 to June 30, 2029. The funding supports research focused on understanding the molecular mechanisms underlying increased neuropeptide Y (NPY) release in cardiac sympathetic neurons during sympatho-excitation, which is linked to negative cardiovascular...